Moreover, HHT more effectively damaged the CD34+/CD38− primary AML cells than CD34+/CD38− cells, and ATO significantly promoted this effect in spite of a lack of an obvious influence on the apoptosis rate of these cells when treated alone (Additional file 6: Figure S6). The gene discussed is CD34; the disease is acute myeloid leukemia.